Skip to search formSkip to main contentSkip to account menu

TKI 258

Known as: TKI-258, TKI258 
National Institutes of Health

Related topics

Related topics

2 relations
CHIR-258Dovitinib Lactate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell…
4566 Background: Emerging agents blocking the PD-1 pathway show activity and may transform the current treatment landscape of… 
Review
2013
Review
2013
The N 550 K / H Mutations in FGFR 2 Confer Differential Resistance to PD 173074 , Dovitinib , and Ponatinib ATP-Competitive Inhibitors 1
We sought to identify fibroblast growth factor receptor 2 (FGFR2) kinase domain mutations that confer resistance to the pan-FGFR… 
2012
2012
Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies.
TPS4683 Background: Standard first- and second-line treatments in metastatic renal cell carcinoma (mRCC) target the vascular… 
2011
2011
多西他赛与吉非替尼序贯应用对人肺腺癌细胞SPC-A1生长及信号蛋白的影响
背景与目的 已经证明：化疗联合表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs… 
2010
2010
A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results.
3057 Background: TKI258 selectively targets FGFR1-3, in addition to VEGFR, PDGFR and other tyrosine kinases. FGF pathway has been… 
2010
2010
Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer.
TPS122 Background: Dovitinib (TKI258) is an oral investigational drug that inhibits fibroblast growth factor (FGF), platelet… 
2009
2009
Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder
Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder 
2008
2008
The pharmacodynamic effect of TKI258 on plasma biomarkers of angiogenesis in patients with AML and advanced melanoma
14680 Background: TKI258 (dovitinib lactate), is a multi-tyrosine kinase inhibitor of VEGF receptors-1,2,3, FGF receptors-1, 2, 3… 
2000
2000
TKI Teamklima-Inventar : Manual
1990
1990
Perjalanan nasib TKI-TKW : antara rantai kemiskinan dan nasib perempuan
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)